Saquinavir plus methylprednisolone ameliorates experimental acute lung injury

Glucocorticoid insensitivity is an important barrier to the treatment of several inflammatory diseases, including acute lung injury (ALI). Saquinavir (SQV) is an inhibitor of the human immunodeficiency virus protease, and the therapeutic effects of SQV in ALI accompanied with glucocorticoid insensit...

Full description

Bibliographic Details
Main Authors: Guanghua Zhang, Xue Zhang, Haidi Huang, Yunxia Ji, Defang Li, Wanglin Jiang
Format: Article
Language:English
Published: Associação Brasileira de Divulgação Científica 2018-08-01
Series:Brazilian Journal of Medical and Biological Research
Subjects:
ALI
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2018001000608&lng=en&tlng=en
id doaj-8c767fa05ba840e2a45df1acc17f746b
record_format Article
spelling doaj-8c767fa05ba840e2a45df1acc17f746b2020-11-24T22:21:02ZengAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research1414-431X2018-08-01511010.1590/1414-431x20187579S0100-879X2018001000608Saquinavir plus methylprednisolone ameliorates experimental acute lung injuryGuanghua ZhangXue ZhangHaidi HuangYunxia JiDefang LiWanglin JiangGlucocorticoid insensitivity is an important barrier to the treatment of several inflammatory diseases, including acute lung injury (ALI). Saquinavir (SQV) is an inhibitor of the human immunodeficiency virus protease, and the therapeutic effects of SQV in ALI accompanied with glucocorticoid insensitivity have not been previously investigated. In this study, the effects of SQV on lipopolysaccharide (LPS)-mediated injury in human pulmonary microvascular endothelial cells (HPMECs), human type I alveolar epithelial cells (AT I), and alveolar macrophages were determined. In addition, the effects of SQV on an LPS-induced ALI model with or without methylprednisolone (MPS) were studied. In LPS-stimulated HPMECs, SQV treatment resulted in a decrease of high mobility group box 1 (HMGB1), phospho-NF-κB (p-NF-κB), and toll-like receptor 4 (TLR4), and an increase of VE-cadherin. Compared to MPS alone, MPS plus SQV attenuated the decrease of glucocorticoid receptor alpha (GRα) and IκBα in LPS-stimulated HPMECs. HMGB1, TLR4, and p-NF-κB expression were also lessened in LPS-stimulated alveolar macrophages with SQV treatment. In addition, SQV reduced the injury in human AT I with a decrease of HMGB1 and p-NF-κB, and with an increase of aquaporin 5 (AQP 5). SQV ameliorated the lung injury caused by LPS in rats with reductions in vascular permeability, myeloperoxidase activity (MPO) and histopathological scores, and with lowered HMGB1, TLR4, and p-NF-κB expression, but with enhanced VE-cadherin expression. By comparison, SQV plus MPS increased GRα and IκBα in lung tissues of rats with ALI. This study demonstrated that SQV prevented experimental ALI and improved glucocorticoid insensitivity by modulating the HMGB1/TLR4 pathway.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2018001000608&lng=en&tlng=enSaquinavirALITwo-hitHMGB1TLR4
collection DOAJ
language English
format Article
sources DOAJ
author Guanghua Zhang
Xue Zhang
Haidi Huang
Yunxia Ji
Defang Li
Wanglin Jiang
spellingShingle Guanghua Zhang
Xue Zhang
Haidi Huang
Yunxia Ji
Defang Li
Wanglin Jiang
Saquinavir plus methylprednisolone ameliorates experimental acute lung injury
Brazilian Journal of Medical and Biological Research
Saquinavir
ALI
Two-hit
HMGB1
TLR4
author_facet Guanghua Zhang
Xue Zhang
Haidi Huang
Yunxia Ji
Defang Li
Wanglin Jiang
author_sort Guanghua Zhang
title Saquinavir plus methylprednisolone ameliorates experimental acute lung injury
title_short Saquinavir plus methylprednisolone ameliorates experimental acute lung injury
title_full Saquinavir plus methylprednisolone ameliorates experimental acute lung injury
title_fullStr Saquinavir plus methylprednisolone ameliorates experimental acute lung injury
title_full_unstemmed Saquinavir plus methylprednisolone ameliorates experimental acute lung injury
title_sort saquinavir plus methylprednisolone ameliorates experimental acute lung injury
publisher Associação Brasileira de Divulgação Científica
series Brazilian Journal of Medical and Biological Research
issn 1414-431X
publishDate 2018-08-01
description Glucocorticoid insensitivity is an important barrier to the treatment of several inflammatory diseases, including acute lung injury (ALI). Saquinavir (SQV) is an inhibitor of the human immunodeficiency virus protease, and the therapeutic effects of SQV in ALI accompanied with glucocorticoid insensitivity have not been previously investigated. In this study, the effects of SQV on lipopolysaccharide (LPS)-mediated injury in human pulmonary microvascular endothelial cells (HPMECs), human type I alveolar epithelial cells (AT I), and alveolar macrophages were determined. In addition, the effects of SQV on an LPS-induced ALI model with or without methylprednisolone (MPS) were studied. In LPS-stimulated HPMECs, SQV treatment resulted in a decrease of high mobility group box 1 (HMGB1), phospho-NF-κB (p-NF-κB), and toll-like receptor 4 (TLR4), and an increase of VE-cadherin. Compared to MPS alone, MPS plus SQV attenuated the decrease of glucocorticoid receptor alpha (GRα) and IκBα in LPS-stimulated HPMECs. HMGB1, TLR4, and p-NF-κB expression were also lessened in LPS-stimulated alveolar macrophages with SQV treatment. In addition, SQV reduced the injury in human AT I with a decrease of HMGB1 and p-NF-κB, and with an increase of aquaporin 5 (AQP 5). SQV ameliorated the lung injury caused by LPS in rats with reductions in vascular permeability, myeloperoxidase activity (MPO) and histopathological scores, and with lowered HMGB1, TLR4, and p-NF-κB expression, but with enhanced VE-cadherin expression. By comparison, SQV plus MPS increased GRα and IκBα in lung tissues of rats with ALI. This study demonstrated that SQV prevented experimental ALI and improved glucocorticoid insensitivity by modulating the HMGB1/TLR4 pathway.
topic Saquinavir
ALI
Two-hit
HMGB1
TLR4
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2018001000608&lng=en&tlng=en
work_keys_str_mv AT guanghuazhang saquinavirplusmethylprednisoloneamelioratesexperimentalacutelunginjury
AT xuezhang saquinavirplusmethylprednisoloneamelioratesexperimentalacutelunginjury
AT haidihuang saquinavirplusmethylprednisoloneamelioratesexperimentalacutelunginjury
AT yunxiaji saquinavirplusmethylprednisoloneamelioratesexperimentalacutelunginjury
AT defangli saquinavirplusmethylprednisoloneamelioratesexperimentalacutelunginjury
AT wanglinjiang saquinavirplusmethylprednisoloneamelioratesexperimentalacutelunginjury
_version_ 1725772655619997696